EZH2-IN-3, identified by its CAS number 1377997-28-8, is a small molecule inhibitor specifically targeting the enzyme Enhancer of Zeste Homolog 2 (EZH2), which is a key component of the Polycomb Repressive Complex 2 (PRC2). This compound is primarily studied for its potential therapeutic applications in cancer treatment, particularly in malignancies characterized by aberrant EZH2 activity, such as certain lymphomas and solid tumors. EZH2 plays a crucial role in gene silencing through histone methylation, and its inhibition can lead to reactivation of tumor suppressor genes. EZH2-IN-3 exhibits selective binding affinity for the EZH2 enzyme, which may result in reduced proliferation of cancer cells and induction of apoptosis. The compound's pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are critical for its efficacy and safety profile in clinical settings. Ongoing research aims to elucidate its full therapeutic potential and optimize its use in combination with other cancer therapies.

EZH2-IN-3 is an EZH2 and EZH1 inhibitor with selective impact on diffuse large B cell lymphoma cell growth.

EZH2-IN-3

1377997-28-8: EZH2-IN-3, identified by its CAS number 1377997-28-8, is a small molecule inhibitor specifically targeting the enzyme Enhancer of Zeste Homolog 2 (EZH2), which is a key component of the Polycomb Repressive Complex 2 (PRC2). This compound is primarily studied for its potential therapeutic applications in cancer treatment, particularly in malignancies characterized by aberrant EZH2 activity, such as certain lymphomas and solid tumors. EZH2 plays a crucial role in gene silencing through histone methylation, and its inhibition can lead to reactivation of tumor suppressor genes. EZH2-IN-3 exhibits selective binding affinity for the EZH2 enzyme, which may result in reduced proliferation of cancer cells and induction of apoptosis. The compound's pharmacokinetic properties, including absorption, distribution, metabolism, and excretion, are critical for its efficacy and safety profile in clinical settings. Ongoing research aims to elucidate its full therapeutic potential and optimize its use in combination with other cancer therapies.

<p>EZH2-IN-3 is an inhibitor of EZH2 and EZH1 with selective impact on diffuse large B cell lymphoma cell growth.</p>

CAS 1377997-28-8

EZH2-IN-3

EZH2-IN-3

Ref: TM-T25400